Results 21 to 30 of about 4,616,223 (198)

Artificial Intelligence in Cardiovascular Medicine: Historical Overview, Current Status, and Future Directions.

Texas Heart Institute Journal, 2022
Artificial intelligence and machine learning are rapidly gaining popularity in every aspect of our daily lives, and cardiovascular medicine is no exception.
Z. Krajcer
semanticscholar   +1 more source

Advancing cardiovascular medicine with machine learning: Progress, potential, and perspective

Cell Reports Medicine, 2022
Summary Recent advances in machine learning (ML) have made it possible to analyze high-dimensional and complex data—such as free text, images, waveforms, videos, and sound—in an automated manner by successfully learning complex associations within these ...
Joshua P. Barrios, G. Tison
semanticscholar   +1 more source

Discovering biomarkers associated and predicting cardiovascular disease with high accuracy using a novel nexus of machine learning techniques for precision medicine

bioRxiv, 2023
Personalized interventions are deemed vital given the intricate characteristics, advancement, inherent genetic composition, and diversity of cardiovascular diseases (CVDs). The appropriate utilization of artificial intelligence (AI) and machine learning (
William DeGroat, Habiba Abdelhalim, Kush Patel, Dinesh Mendhe, Saman Zeeshan, Zeeshan Ahmed   +5 more
semanticscholar   +1 more source

After 50 Years of Heart Transplants: What Does the Next 50 Years Hold for Cardiovascular Medicine? A Perspective From the International Society for Applied Cardiovascular Biology

Frontiers in Cardiovascular Medicine, 2019
The first successful heart transplant 50 years ago by Dr.Christiaan Barnard in Cape Town, South Africa revolutionized cardiovascular medicine and research. Following this procedure, numerous other advances have reduced many contributors to cardiovascular
Joshua D. Hutcheson, Craig J. Goergen, Frederick J. Schoen, Masanori Aikawa, Peter Zilla, Elena Aikawa, Glenn R. Gaudette   +6 more
doaj   +1 more source

Poor quality sleep is associated with greater carotid intima media thickness among otherwise healthy resident doctors

Frontiers in Epidemiology, 2023
BackgroundSleep is important for maintaining the metabolic processes in the body, and hence, disruption in sleep leads to metabolic derangement and accelerated atherosclerosis. The effect of sleep duration on subclinical atherosclerosis has been examined
Prativa Priyadarshani Sethi, Monika Pathania, Ravi Gupta, Pankaj Sharma, Lokesh Kumar Saini   +4 more
doaj   +1 more source

Clinical decision support in cardiovascular medicine

British medical journal, 2021
Despite considerable progress in tackling cardiovascular disease over the past 50 years, many gaps in the quality of care for cardiovascular disease remain.
Yuan Lu, E. Melnick, H. Krumholz
semanticscholar   +1 more source

Tripartite motif 38 attenuates cardiac fibrosis after myocardial infarction by suppressing TAK1 activation via TAB2/3 degradation

iScience, 2022
Summary: The role of tripartite motif (TRIM) 38, a ubiquitin E3 ligase regulating various pathophysiological processes, in cardiac fibrosis remains unclear.
Zhengri Lu, Chunshu Hao, Hao Qian, Yuanyuan Zhao, Xiangwei Bo, Yuyu Yao, Genshan Ma, Lijuan Chen   +7 more
doaj   +1 more source

SGLT2 Inhibitors in Cardiovascular Medicine.

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
Department of Medicine, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, 1300 Morris Park Avenue, New York, NY 10461, USA; and Department of Molecular ...
Fahimeh Varzideh, U. Kansakar, G. Santulli   +2 more
semanticscholar   +1 more source

A Comprehensive Review on Advancements in Wearable Technologies: Revolutionizing Cardiovascular Medicine

Cureus
Wearable technologies have emerged as powerful tools in healthcare, offering continuous monitoring and personalized insights outside traditional clinical settings.
Vaishnavi Bhaltadak, B. Ghewade, Seema Yelne   +2 more
semanticscholar   +1 more source

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Toda Kato, A. Cahn, Michael G. Silverman, Thomas A. Zelniker, J. Kuder, S. Murphy, Deepak L. Bhatt, Lawrence A Leiter, Darren K Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine   +19 more
semanticscholar   +1 more source